Systematic review: secondary prevention with band ligation, pharmacotherapy or combination therapy after bleeding from oesophageal varices

被引:29
作者
Cheung, J. [1 ,2 ]
Zeman, M. [1 ,2 ]
van Zanten, S. V. [1 ,2 ]
Tandon, P. [1 ,2 ]
机构
[1] Univ Alberta, Dept Med, Div Gastroenterol, Edmonton, AB, Canada
[2] Capital Hlth, Edmonton, AB, Canada
关键词
ISOSORBIDE MONONITRATE ISMN; RANDOMIZED CONTROLLED-TRIAL; PLUS PROPRANOLOL P; ENDOSCOPIC LIGATION; PORTAL-HYPERTENSION; GASTROESOPHAGEAL VARICES; CIRRHOTIC-PATIENTS; NADOLOL; PROPHYLAXIS; HEMORRHAGE;
D O I
10.1111/j.1365-2036.2009.04075.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
P>Background Variable methods are available for secondary prevention after oesophageal variceal bleeding (EVB). Aim To compare band ligation (BL), pharmacotherapy (PT) and BL+PT for EVB secondary prevention. Methods A systematic search of databases, references and meeting abstracts was conducted for randomized trials of BL, PT or BL+PT. The outcomes were mortality, rebleeding and adverse events. A random-effects model was used for meta-analyses. Results Twelve trials were included (6 BL vs. PT, 4 BL+PT vs. BL, 2 BL+PT vs. PT). All trials used beta-blockers +/- isosorbide mononitrate (ISMN) as PT. Mortality was not significantly different among trials. Rebleeding was not significantly different for BL vs. PT (RR 1.00, 95% CI 0.73-1.37). BL reduced rebleeding compared with PT for trials with mean beta-blocker dose < 80 mg/day (RR 0.67, 95% CI 0.49-0.91). There were nonsignificant differences in rebleeding for BL+PT vs. BL (RR 0.57, 95% CI 0.31-1.08) and BL+PT vs. PT (RR 0.76, 95% CI 0.56-1.03). There was no difference in adverse events between BL vs. PT, but was higher with BL+PT vs. BL. Conclusion Band ligation and PT alone are comparable for secondary prevention of rebleeding after EVB. Further trials with adequate PT dosing are required to determine the efficacy of combination BL+PT therapy.
引用
收藏
页码:577 / 588
页数:12
相关论文
共 42 条
[1]   Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis [J].
Abraldes, JG ;
Tarantino, I ;
Turnes, J ;
Garcia-Pagan, JC ;
Rodés, J ;
Bosch, J .
HEPATOLOGY, 2003, 37 (04) :902-908
[2]  
[Anonymous], 2001, SYSTEMATIC REV HLTH
[3]  
[Anonymous], GUT S7
[4]  
AUBERT A, 1993, GASTROEN CLIN BIOL, V17, P403
[5]   Acute management and secondary prophylaxis of esophageal variceal bleeding: A western Canadian survey [J].
Cheung, Justin ;
Wong, Winnie ;
Zandieh, Iman ;
Leung, Yvette ;
Lee, Samuel S. ;
Ramji, Alnoor ;
Yoshida, Eric M. .
CANADIAN JOURNAL OF GASTROENTEROLOGY, 2006, 20 (08) :531-534
[6]   Evolving consensus in portal hypertension - Report of the Baveno IV Consensus Workshop on methodology of diagnosis and therapy in portal hypertension [J].
de Franchis, R .
JOURNAL OF HEPATOLOGY, 2005, 43 (01) :167-176
[7]   Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding:: A multicenter trial [J].
de la Peña, J ;
Brullet, E ;
Sanchez-Hernández, E ;
Rivero, M ;
Vergara, M ;
Martin-Lorente, JL ;
Suárez, CG .
HEPATOLOGY, 2005, 41 (03) :572-578
[8]   Variceal ligation plus nadolol compared with variceal ligation after bleeding. Multicenter randomized trial. Preliminary analysis [J].
De La Pena, J ;
Rivero, M ;
Suarez, CG ;
Brullet, E ;
Campo, R ;
Vergara, M ;
Hernandez, ES ;
Lorente, JLM .
GASTROENTEROLOGY, 2003, 124 (04) :A733-A733
[9]   Endoscopic histoacryl obliteration vs. propranolol in the prevention of esophagogastric variceal rebleeding:: A randomized trial [J].
Evrard, S ;
Dumonceau, JM ;
Delhaye, M ;
Golstein, P ;
Devière, J ;
Le Moine, O .
ENDOSCOPY, 2003, 35 (09) :729-735
[10]  
Gallego A, 1997, GASTROINTEST ENDOSC, V45, P176